Skip to content
Screener

Viatris VTRS Q2 2026 earnings

Reported August 6, 2026 · Before market open

Revenue$3.8BBeat by $81.4M
EPS$0.69Beat by $0.09
Revenue estimate$3.7B
EPS estimate$0.60
“Our second-quarter results reflect another quarter of strong execution and reinforce the momentum we're building across our business. Commercial execution, pipeline progress and the early benefits of our enterprise-wide strategic review continue strengthening our business and improving our financial performance. Our strong first-half results give us the confidence to raise our full-year guidance. We expect a more balanced operating environment in the second half of the year and we remain focused on disciplined execution, investing behind our future growth drivers and creating long-term value for patients and shareholders.”
Scott A. Smith

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$3.8B
EPS estimate$0.67

Financials

Q2 2026

Income statement

See full
Revenue$3.8B+4.9%
Gross profit$1.5B+9.3%
Operating income$6.3M-97.3%
Net income-$118.8M-2,483%
EPS (diluted)-$0.10—

Balance sheet

See full
Cash & equivalents$890.0M+56.7%
Total debt$13.6B-7.7%
Total equity$14.3B-8.4%
Total assets$35.0B-8.8%

Cash flow

See full
Operating cash flow$381.8M+73.8%
CapEx$52.8M-0.2%
Free cash flow$329.0M+97.2%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$19.35B+59.3%
Enterprise value$32.09B+21.8%
P/S1.3×+0.5×

Profitability

See full
Gross margin34.8%-1.8pp
Operating margin-0.6%—
Net margin-2.8%-1.3pp
FCF margin13.3%+0.9pp

Returns & leverage

See full
Return on equity-2.8%-1.3pp
Debt / equity1×0.0×
Current ratio1.6×+0.2×

Segments

By product

See full
Brands$2.4B+5.9%
Generics$1.3B+3.3%
Lipitor$452.2M+16.6%
Norvasc$200.2M+9.6%
EpiPen® Auto-Injectors$129.2M-5.6%

By segment

See full
Developed Markets Segment$2.2B+3.4%
Greater China$713.8M+21.2%
Emerging Markets Segment$543.8M-2.4%
Japan, Australia and New Zealand Segment$296.2M-3.4%

FAQ

When did Viatris report Q2 2026 earnings?
Viatris (VTRS) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Viatris's Q2 2026 revenue and EPS?
Viatris reported revenue of $3.8B and eps of $0.69 for Q2 2026.
Did Viatris beat estimates in Q2 2026?
Revenue beat the consensus estimate of $3.7B by $81.4M. EPS beat the consensus estimate of $0.60 by $0.09.
How did Viatris's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 4.9% from $3.6B a year earlier and eps grew 11.3% from $0.62.
Where can I find Viatris's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001792044-26-000037) and the 10-Q periodic report (0001792044-26-000041) directly on SEC EDGAR. The filing index links above go to sec.gov.